Matches in SemOpenAlex for { <https://semopenalex.org/work/W4321783833> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W4321783833 endingPage "e843" @default.
- W4321783833 startingPage "e843" @default.
- W4321783833 abstract "Triplet regimens containing immunomodulatory drugs and proteasome inhibitors (PIs) have improved outcomes and extended survival for patients with relapsed/refractory multiple myeloma (RRMM). We evaluated updated health-related quality of life (HRQoL) findings from the phase 2 ELOQUENT-3 clinical trial (NCT02654132) after 4 years of treatment with elotuzumab plus pomalidomide and dexamethasone (EPd) and assessed the impact of the addition of elotuzumab on patients' HRQoL. HRQoL was assessed as an exploratory endpoint using the MD Anderson Symptom Inventory for Multiple Myeloma (MDASI-MM), which evaluates symptom severity, symptom interference, and HRQoL, and the 3-level EQ-5D, a patient-reported measure of health utility and general health. Statistical analyses included descriptive responder, longitudinal mixed-model, and time-to-first-deterioration (TTD) analyses using prespecified minimally important differences and responder definitions. Of 117 randomized patients, 106 (EPd, n = 55; pomalidomide and dexamethasone [Pd], n = 51) were eligible for inclusion in HRQoL analyses. Completion rates at almost all on-treatment visits were ≥80%. The proportion of patients treated with EPd who improved or maintained stable HRQoL until cycle 13 ranged from 82% to 96% for MDASI-MM total symptom score and 64% to 85% for MDASI-MM symptom interference. Across measurements, there were no clinically meaningful differences in changes from baseline between treatment arms, and TTD was not significantly different for EPd versus Pd. In conclusion, HRQoL was not impacted by the addition of elotuzumab to Pd and did not significantly deteriorate in patients with RRMM previously treated with lenalidomide and a PI in ELOQUENT-3." @default.
- W4321783833 created "2023-02-25" @default.
- W4321783833 creator A5012405296 @default.
- W4321783833 creator A5022522496 @default.
- W4321783833 creator A5025803229 @default.
- W4321783833 creator A5029205753 @default.
- W4321783833 creator A5037803243 @default.
- W4321783833 creator A5066221397 @default.
- W4321783833 creator A5068721338 @default.
- W4321783833 creator A5071926851 @default.
- W4321783833 creator A5077284234 @default.
- W4321783833 creator A5086422682 @default.
- W4321783833 creator A5089163384 @default.
- W4321783833 date "2023-02-24" @default.
- W4321783833 modified "2023-10-18" @default.
- W4321783833 title "Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial" @default.
- W4321783833 cites W1964685529 @default.
- W4321783833 cites W1977733462 @default.
- W4321783833 cites W1994222210 @default.
- W4321783833 cites W1999549312 @default.
- W4321783833 cites W2098428600 @default.
- W4321783833 cites W2106545856 @default.
- W4321783833 cites W2150868131 @default.
- W4321783833 cites W2160088903 @default.
- W4321783833 cites W2770457793 @default.
- W4321783833 cites W2900068404 @default.
- W4321783833 cites W2983430492 @default.
- W4321783833 cites W3007296830 @default.
- W4321783833 cites W3093835197 @default.
- W4321783833 cites W3125352349 @default.
- W4321783833 cites W3212423155 @default.
- W4321783833 cites W3212813399 @default.
- W4321783833 cites W4290879625 @default.
- W4321783833 cites W4321783833 @default.
- W4321783833 doi "https://doi.org/10.1097/hs9.0000000000000843" @default.
- W4321783833 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36860268" @default.
- W4321783833 hasPublicationYear "2023" @default.
- W4321783833 type Work @default.
- W4321783833 citedByCount "1" @default.
- W4321783833 countsByYear W43217838332023 @default.
- W4321783833 crossrefType "journal-article" @default.
- W4321783833 hasAuthorship W4321783833A5012405296 @default.
- W4321783833 hasAuthorship W4321783833A5022522496 @default.
- W4321783833 hasAuthorship W4321783833A5025803229 @default.
- W4321783833 hasAuthorship W4321783833A5029205753 @default.
- W4321783833 hasAuthorship W4321783833A5037803243 @default.
- W4321783833 hasAuthorship W4321783833A5066221397 @default.
- W4321783833 hasAuthorship W4321783833A5068721338 @default.
- W4321783833 hasAuthorship W4321783833A5071926851 @default.
- W4321783833 hasAuthorship W4321783833A5077284234 @default.
- W4321783833 hasAuthorship W4321783833A5086422682 @default.
- W4321783833 hasAuthorship W4321783833A5089163384 @default.
- W4321783833 hasBestOaLocation W43217838331 @default.
- W4321783833 hasConcept C126322002 @default.
- W4321783833 hasConcept C143998085 @default.
- W4321783833 hasConcept C159110408 @default.
- W4321783833 hasConcept C1862650 @default.
- W4321783833 hasConcept C2776063141 @default.
- W4321783833 hasConcept C2776364478 @default.
- W4321783833 hasConcept C2778524551 @default.
- W4321783833 hasConcept C2779951463 @default.
- W4321783833 hasConcept C2780108899 @default.
- W4321783833 hasConcept C2780401358 @default.
- W4321783833 hasConcept C2781098529 @default.
- W4321783833 hasConcept C71924100 @default.
- W4321783833 hasConceptScore W4321783833C126322002 @default.
- W4321783833 hasConceptScore W4321783833C143998085 @default.
- W4321783833 hasConceptScore W4321783833C159110408 @default.
- W4321783833 hasConceptScore W4321783833C1862650 @default.
- W4321783833 hasConceptScore W4321783833C2776063141 @default.
- W4321783833 hasConceptScore W4321783833C2776364478 @default.
- W4321783833 hasConceptScore W4321783833C2778524551 @default.
- W4321783833 hasConceptScore W4321783833C2779951463 @default.
- W4321783833 hasConceptScore W4321783833C2780108899 @default.
- W4321783833 hasConceptScore W4321783833C2780401358 @default.
- W4321783833 hasConceptScore W4321783833C2781098529 @default.
- W4321783833 hasConceptScore W4321783833C71924100 @default.
- W4321783833 hasIssue "3" @default.
- W4321783833 hasLocation W43217838331 @default.
- W4321783833 hasLocation W43217838332 @default.
- W4321783833 hasLocation W43217838333 @default.
- W4321783833 hasLocation W43217838334 @default.
- W4321783833 hasOpenAccess W4321783833 @default.
- W4321783833 hasPrimaryLocation W43217838331 @default.
- W4321783833 hasRelatedWork W2123159083 @default.
- W4321783833 hasRelatedWork W2200095709 @default.
- W4321783833 hasRelatedWork W2345487218 @default.
- W4321783833 hasRelatedWork W2478188943 @default.
- W4321783833 hasRelatedWork W2590875813 @default.
- W4321783833 hasRelatedWork W2618355916 @default.
- W4321783833 hasRelatedWork W2734396891 @default.
- W4321783833 hasRelatedWork W2900068404 @default.
- W4321783833 hasRelatedWork W2980591007 @default.
- W4321783833 hasRelatedWork W3213371026 @default.
- W4321783833 hasVolume "7" @default.
- W4321783833 isParatext "false" @default.
- W4321783833 isRetracted "false" @default.
- W4321783833 workType "article" @default.